Ptsd - Articles - Page 3 | CARLAT PUBLISHING

Another Black Eye for Prazosin in PTSD?

August 1, 2019

Nicholas Rosenlicht, MD Dr. Rosenlicht has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Recent trials cast doubt on prazosin’s role in PTSD, but there are reasons to doubt their results.

The Carlat Report Goes to APA Part II

July 29, 2019

More highlights from the American Psychiatric Association's 2019 meeting in the final installment of this two-part series. Expert interviews with Manpreet Singh on childhood mood disorders and Nikhil Rao on novel medications for sleep. Learn what to do when children get worse on antidepressants, and how to use clonidine...

Off-Label Use of Medications for PTSD

June 30, 2019

In The Carlat Child Psychiatry Report, Elizabeth Tien, MD, a child & adolescent psychiatrist at Maimonides Medical Center in Brooklyn, NY, offers off-label advice on prescribing medications for children with PTSD. Below are some general tips, but to get a handy table on which meds to choose and how to...

Co-Occurring Addiction and PTSD

May 21, 2019

Dolores Vojvoda, MD

Dolores Vojvoda, MD
Assistant Professor of Psychiatry, Yale School of Medicine

Dr. Vojvoda has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Individuals who have PTSD have a high risk of developing other disorders, including substance use disorders (SUDs). Studies have shown that both in the veteran and non-veteran populations, these numbers are high.

Sleep and PTSD

April 10, 2019

Michael McCarthy, MD

Michael McCarthy, MD

Associate Adjunct Professor, Department of Psychiatry, University of California at San Diego. Dr. McCarthy has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Insomnia is different in PTSD. Some of that is explained by the symptoms of PTSD, such as nightmares, hyperarousal, anxiety, and physical restlessness. But there’s another thing we’re seeing that isn’t as obvious: sleep apnea.

Note From the Editor-in-Chief

December 1, 2017

Daniel Carlat, MD

Daniel Carlat, MD Editor-in-Chief, The Carlat Psychiatry Report.

My goal in publishing TCPR is to help you think differently about your clinical practice, hopefully to enhance your effectiveness as a healer. After editing this month’s issue on posttraumatic stress disorder (PTSD), I think I’ve achieved that goal in my own practice.

Update on Medications for PTSD

December 1, 2017

Robin Berlin, MD and Daniel Carlat, MD

Robin Berlin, MD Assistant clinical professor of psychiatry, George Washington University School of Medicine, and director of psychiatry, La Clinica del Pueblo, Washington, DC. Daniel Carlat, MD Editor-in-chief, The Carlat Psychiatry Report. Dr. Berlin and Dr. Carlat have disclosed that they have no relevant relationships or financial interests in any commercial company pertaining to this educational activity.

Every five years or so, we do an update on PTSD treatments; the most recent was our August 2011 issue of TCPR, in which we declared that psychotherapy was the gold standard for treatment.

Assessing Complex PTSD

December 1, 2017

Arielle Schwartz, PhD

Arielle Schwartz, PhD Licensed clinical psychologist in private practice in Boulder, CO. Author of The Complex PTSD Workbook: A Mind-Body Approach to Regaining Emotional Control and Becoming Whole. Dr. Schwartz has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

The first thing that I would say is that complex PTSD can sometimes be harder to spot and diagnose, because when we’re looking for symptoms of conventional PTSD, we’re often looking for that first criterion: Has there been a single event that your patient would consider traumatic?

Efficacy of Quetiapine in PTSD

October 17, 2016

Bret A. Moore, PsyD, ABPP

...

Efficacy of Quetiapine in PTSD

October 1, 2016

Bret A. Moore, PsyD, ABPP

Bret A. Moore, PsyD, ABPP. Board-Certified Clinical Psychologist, San Antonio, TX
Dr. Moore has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Some smaller studies have shown that risperidone is useful as an adjunctive treatment for PTSD. But, in a larger-scale study with nearly 300 veterans, the medication used as an adjunct did not outperform placebo. To further explore the utility of atypical antipsychotics, researchers randomly assigned 80 VA patients with PTSD to monotherapy with placebo or quetiapine.